AU2014233521A1 - Ganglioside compositions - Google Patents

Ganglioside compositions Download PDF

Info

Publication number
AU2014233521A1
AU2014233521A1 AU2014233521A AU2014233521A AU2014233521A1 AU 2014233521 A1 AU2014233521 A1 AU 2014233521A1 AU 2014233521 A AU2014233521 A AU 2014233521A AU 2014233521 A AU2014233521 A AU 2014233521A AU 2014233521 A1 AU2014233521 A1 AU 2014233521A1
Authority
AU
Australia
Prior art keywords
ganglioside
cells
cell
mobile phase
clq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2014233521A
Other languages
English (en)
Inventor
Vandana MADANLAL SHARMA
Vanessa Ragaglia
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Garnet BioTherapeutics Inc
Original Assignee
Garnet BioTherapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Garnet BioTherapeutics Inc filed Critical Garnet BioTherapeutics Inc
Publication of AU2014233521A1 publication Critical patent/AU2014233521A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7032—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a polyol, i.e. compounds having two or more free or esterified hydroxy groups, including the hydroxy group involved in the glycosidic linkage, e.g. monoglucosyldiacylglycerides, lactobionic acid, gangliosides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H3/00—Compounds containing only hydrogen atoms and saccharide radicals having only carbon, hydrogen, and oxygen atoms
    • C07H3/06—Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P19/00—Preparation of compounds containing saccharide radicals
    • C12P19/44—Preparation of O-glycosides, e.g. glucosides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Epidemiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Psychology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Saccharide Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
AU2014233521A 2013-03-15 2014-03-14 Ganglioside compositions Abandoned AU2014233521A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361799519P 2013-03-15 2013-03-15
US61/799,519 2013-03-15
PCT/US2014/029569 WO2014144953A1 (en) 2013-03-15 2014-03-14 Ganglioside compositions

Publications (1)

Publication Number Publication Date
AU2014233521A1 true AU2014233521A1 (en) 2015-08-20

Family

ID=51537838

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2014233521A Abandoned AU2014233521A1 (en) 2013-03-15 2014-03-14 Ganglioside compositions

Country Status (11)

Country Link
US (1) US20150025234A1 (es)
EP (1) EP2968378A4 (es)
JP (1) JP2016521967A (es)
CN (1) CN105142645A (es)
AU (1) AU2014233521A1 (es)
CA (1) CA2905700A1 (es)
IL (1) IL240687A0 (es)
MX (1) MX2015012798A (es)
SG (1) SG11201506311YA (es)
WO (1) WO2014144953A1 (es)
ZA (1) ZA201505738B (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2581523T3 (es) 2009-09-01 2016-09-06 Lz Therapeutics, Inc. Producción en cultivo celular (no bovino, no porcino) de GM1
US9556467B2 (en) 2012-01-20 2017-01-31 Garnet Bio Therapeutics, Inc. Methods of ganglioside production
JP6557575B2 (ja) * 2015-10-23 2019-08-07 株式会社Adeka エッチング液組成物及びエッチング方法
CN105738527B (zh) * 2016-03-11 2018-06-29 北京市药品检验所 使用氨基酸分析仪测定氨基葡萄糖的方法
CN109721632B (zh) * 2017-10-27 2023-10-31 齐鲁制药有限公司 一种高纯度神经节苷脂gm1及其制备方法
CN114965822B (zh) * 2017-10-27 2024-06-04 齐鲁制药有限公司 高效测定神经节苷脂gm1及其杂质的药物分析方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES528692A0 (es) * 1984-01-04 1985-07-01 Bioiberica Procedimiento para la obtencion de un complejo glicoesfingolipidico
IT1199116B (it) * 1984-07-03 1988-12-30 Fidia Farmaceutici Derivati di gangliosidi
US5532141A (en) * 1995-06-13 1996-07-02 Holler; Larry D. Process for obtaining ganglioside lipids
US7851451B2 (en) * 2004-03-12 2010-12-14 Mti Meta Tech Inc. Formulations for mediating inflammatory bowel disorders
ES2581523T3 (es) * 2009-09-01 2016-09-06 Lz Therapeutics, Inc. Producción en cultivo celular (no bovino, no porcino) de GM1
US9556467B2 (en) * 2012-01-20 2017-01-31 Garnet Bio Therapeutics, Inc. Methods of ganglioside production

Also Published As

Publication number Publication date
EP2968378A4 (en) 2016-08-31
MX2015012798A (es) 2016-06-10
CA2905700A1 (en) 2014-09-18
EP2968378A1 (en) 2016-01-20
US20150025234A1 (en) 2015-01-22
SG11201506311YA (en) 2015-09-29
JP2016521967A (ja) 2016-07-28
CN105142645A (zh) 2015-12-09
IL240687A0 (en) 2015-10-29
WO2014144953A1 (en) 2014-09-18
ZA201505738B (en) 2017-11-29

Similar Documents

Publication Publication Date Title
AU2014233521A1 (en) Ganglioside compositions
US20220073959A1 (en) Methods of ganglioside production
JP5552421B2 (ja) エキソグリコシダーゼを用いるｎ−グリカンの特性決定法
Heiskanen et al. Glycomics of bone marrow-derived mesenchymal stem cells can be used to evaluate their cellular differentiation stage
EP2205972A1 (en) In vivo isotopic labeling method for quantitative glycomics
De Marino et al. Bioactive asterosaponins from the starfish Luidia quinaria and Psilaster cassiope. Isolation and structure characterization by two-dimensional NMR spectroscopy
Wu et al. Anticoagulant and FGF/FGFR signal activating activities of the heparinoid propylene glycol alginate sodium sulfate and its oligosaccharides
Chan et al. Transition state analysis of Vibrio cholerae sialidase-catalyzed hydrolyses of natural substrate analogues
Schilling et al. Biosynthesis of sialylated lipooligosaccharides in Haemophilus ducreyi is dependent on exogenous sialic acid and not mannosamine. Incorporation studies using N-acylmannosamine analogues, N-glycolylneuraminic acid, and 13C-labeled N-acetylneuraminic acid
Kaur et al. Effect of high glucose on glycosaminoglycans in cultured retinal endothelial cells and rat retina
Hancock et al. N-acetylneuraminic acid and sialoglycoconjugate metabolism in fibroblasts from a patient with generalized N-acetylneuraminic acid storage disease
Yang et al. Structures and biosynthesis of the N-and O-glycans of recombinant human oviduct-specific glycoprotein expressed in human embryonic kidney cells
Kim et al. Establishment of N‐acetylmannosamine (ManNAc) analogue‐resistant cell lines as improved hosts for sialic acid engineering applications
Chen et al. Quantitative analysis of the major linkage region tetrasaccharides in heparin
Wang et al. Comprehensive investigation of milk oligosaccharides in different mammalian species and the effect of breed and lactation period on sheep milk oligosaccharides
Mannelli et al. Pyruvate prevents the onset of the cachectic features and metabolic alterations in myotubes downregulating STAT3 signaling
AU2013204410A1 (en) Methods of ganglioside production
Pungor Jr et al. Development of a functional bioassay for arylsulfatase B using the natural substrates of the enzyme
Tomar Profiling Ganglioside Expression and Change in THP-1 Macrophages Upon LPS Stimulation
Miura et al. Characterization of mammalian UDP-GalNAc: glucuronide α1-4-N-acetylgalactosaminyltransferase
Tong et al. Identification and characterization of emGalaseE, a β-1, 4 galactosidase from Elizabethkingia meningoseptica, and its application on living cell surface
Yoshimi et al. Developmental changes in Asn-linked neutral oligosaccharides in murine cerebrum
Tong et al. Identification and characterization of a beta-1, 4 Galactosidase from Elizabethkingia meningoseptica and its application on living cell surface
Saito et al. Occurrence and tissue distribution of c-series gangliosides in the common squid Todarodes pacificus
Frankenberger et al. Incomplete Elongation of the Chondroitin Sulfate Linkage Region on Aggrecan and Response to Interleukin-1β

Legal Events

Date Code Title Description
MK5 Application lapsed section 142(2)(e) - patent request and compl. specification not accepted